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INTRODUCTION: The differential diagnosis of B-cell lymphoproliferative processes remains a challenge for pathologists, der-
matologists and oncologists, despite advances in histology, immunohistochemistry and molecular biology. 
OBJECTIVE: Evaluate aid and limitations of clonality analysis in the diagnosis of primary cutaneous B-cell lymphomas and 
B-cell pseudolymphomas.
METHODS: This study included 29 cases of B-cell lymphoproliferative processes classified as primary cutaneous B-cell lym-
phomas (13), B-cell pseudolymphomas (6) and inconclusive cases (10) using histology and immunohistochemistry. The clonality 
analysis was performed by polymerase chain reaction analysis of immunoglobulin light chain and heavy chain rearrangements. 
RESULTS: DNA quality was shown to be generally poor; eight samples were inadequate for polymerase chain reaction analysis. 
The results showed monoclonality in eight of the primary cutaneous B-cell lymphomas and polyclonality in four of the B-cell 
pseudolymphomas. In addition, monoclonality was shown in two of the inconclusive cases by histology and immunohistochemistry, 
demonstrating the utility of polymerase chain reaction as an ancillary diagnostic tool for primary cutaneous B-cell lymphomas.
DISCUSSION: The low quality DNA extracted from these cases demanded the use of an IgH protocol that yielded small fragments 
and IgK. Both methods used together improved detection.
CONCLUSION: Use of the two protocols, immunoglobulin heavy chain FR3-trad and immunoglobulin light chain-Kappa Biomed 
protocols for clonality analysis improved diagnostic accuracy.
KEYWORDS: Cutaneous lymphoma; Polymerase chain reaction; Gene rearrangement; Clonality; B-cell; Lymphoproliferative 
processes.
INTRODUCTION
B-cell lymphoproliferative processes, including primary 
cutaneous B-cell lymphomas (PCBCLs) and B-cell 
pseudolymphomas (B-PSLs), have been exhaustively 
studied in the last few decades.1,2 Nevertheless, differential 
diagnosis between the two entities remains a challenge 
for dermatopathologists, hematologists, dermatologists 
and oncologists ,  despite advances in histology, 
immunohistochemistry and molecular biology.3-6
The clinical history and physical examination contribute 
to the differential diagnosis of PCBCL; however, the 
diagnostic investigation is largely composed of histological 
and immunohistochemical studies.7,8 Molecular biology 
techniques have been described as important ancillary 
diagnostic tools in difficult cases.9,10 Recently, analysis 
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of clonality through investigation of immunoglobulin 
light and heavy chain gene rearrangements has been used 
to supplement the diagnosis of PCBCL.9,11,12 Usually, 
polymerase chain reaction (PCR) is the molecular technique 
of choice due to higher sensitivity and lower cost when 
compared with Southern blot. As an additional advantage, 
this tool offers the possibility to work with formalin-fixed 
and paraffin-embedded tissue.12-14
PCR has been very useful in the diagnosis of PCBCL 
when used to investigate rearrangement of the IgH gene 
located on chromosome 14 (14q32).15,16 The rearrangement 
of IgH genes is the first rearrangement event to take place in 
the differentiation of B cells, preceding that of the IgL genes, 
and it is present in the majority of PCBCLs.17 As several 
regions (FR3, FR2, and FR1) of IgH genes can be evaluated, 
a number of protocols have been developed. These include 
the Biomed-2 protocols and more traditional ones.14,18,19
Sensitivity can vary from less than 20% to more than 
90%, depending on the employed method. 9,13,20 In some 
cases, it is not possible to amplify the IgH gene because 
primers fail to bind to the rearrangement that occurred 
in the neoplastic B lymphocytes or an inadequate DNA 
sample. Rearrangement of the IgL-K (2q12) and IgL lambda 
(22q11) genes can also be investigated and may increase the 
diagnostic sensitivity up to 93%, particularly when combined 
with IgH analysis.11, 20, 21 
In the present study, the impact of the analysis of IgH 
and IgL-K gene rearrangement in the diagnosis of B-cell 
lymphoproliferative cutaneous processes and the limitations 
of these methods are assessed.
DIAGNOSTIC METHOD
Twenty-nine patients with B-cell lymphoproliferative 
processes were evaluated. Clinical data were retrieved from 
the clinical records, and all cases were classified according 
to the histological and immunohistochemical characteristics. 
We included cases diagnosed by two dermatopathologists 
who were experts in cutaneous lymphoma without prior 
knowledge of the clinical setting. The pathologists 
established a diagnosis of PCBCL (13 cases) or B-PSL 
(6 cases). Whenever there was a discrepancy between the 
diagnoses of both pathologists or when they could not 
define the diagnosis, the case was considered inconclusive 
(10 cases) (Table 1). When the diagnosis of PCBCL was 
established, the cases were classified according to the WHO-
EORTC 2005 Classification.22
Clonality was investigated by IgH gene rearrangement 
using protocols for IgH FR2 (Biomed IgH tube B), IgH FR3 
(Biomed IgH tube C) and a traditional method for IgH FR3 
(IgH-trad), which yields smaller fragments than the Biomed 
protocols.14,23 The investigation of immunoglobulin light 
chain (IgL) gene rearrangement was carried out using the 
IgL Kappa protocols (Biomed Igkappa tubes A and B). 
DNA extraction (crude lysate method): Five sections 
of 10 mm formalin-fixed and paraffin-embedded cutaneous 
biopsies were deparaffinized in xylene and ethanol. Tissue 
digestion was carried out in 100 µl of a solution containing 
200 mg/ml proteinase K (Sigma, UK) in 1 X PCR buffer 
(Sigma, UK). The material was incubated at 37°C for 24 
hours and heated at 95°C for 15 minutes to deactivate the 
proteinase K. A total of 1 µl of the supernatant was used as 
template for DNA amplification.
DNA amplification A mastermix solution composed of 
1 X Buffer II, 200 mM each dNTP (Promega, UK), 1.5 mM 
MgCl2, 1 unit Amplitaq Gold (Applied Biosystems), and 10 
pmol each specific primer (MWG, Germany) was added to 
a reaction microtube (Table 2). A total of 1 ml of DNA was 
added to the mastermix. Cycling parameters were as follows: 
95°C, 7 min, 1 cycle; 93°C, 45 s; 60°C, 45 s; 72°C, 1 min 30 
s, 40 cycles; 72°C, 5 min, 1 cycle. For the FR3-trad protocol, 
the cycling parameters were as follows: 95°C, 7 min, 1 
cycle; 93°C, 45 s; 55°C, 45 s; 72°C, 1 min 30 s, 40 cycles; 
72°C, 5 min, 1 cycle.
PCR Analysis The IgH, IgL kappa and TCR-gamma 
genes are shown in Table 2. A negative control (no template) 
and a positive control (B-cell lymphoma) were used in each 
reaction. Amplification of non-rearranging genes to yield 
products of 100-400 bp was performed as a DNA quality 
control for each sample.14 
Electrophoresis The PCR products (8 µl) were run 
on 6% or 8% polyacrylamide gels. Electrophoresis was 
performed at 200 V for 40 minutes, gels were stained with 
0.5 µg/mL ethidium bromide for 5 minutes and the DNA 
bands were documented by use of the Gel Documentation 
System 1000 (Bio-Rad).
Evaluation of the Band Patterns The band patterns 
were analyzed, and each case was classified as follows: 
(i) Monoclonal (when one or two dominant bands of the 
same size were visualized in duplicate amplifications); (ii) 
Polyclonal (when a smear or variable ladder was detected); 
and (iii) Non-informative (when absence of bands or weak, 
non-reproducible patterns were observed) (Figure 1A). 
A case was defined as monoclonal when at least one of 
the reactions showed a monoclonal pattern, independent 
of the results obtained from other reactions with different 
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Table 1 - Clinical, histological and immunohistochemical data for 29 cases with B-cell lymphoproliferative processes
I G A Dist Localization Morphology Diam N HE IHC IHC HE+IHC L, M, V Stage Status
1 M 54 reg face, neck,
trunk, back papule, nodule 1 10 PCBCL
Anti-CD20 + CD10+, 
BCL-2-, CD23- PCBCL PCBCL Y,Y,Y system DWD (36)
2 F 57 loc back plaque 6 2 INC Anti-CD20 + CD10 -, BCL-2 +, CD23+ INC INC N,N,N cut ativ AWD (78)
3 M 76 loc LL nodule, plaque 16 1 PCBCL(+) Anti-CD20 + CD10 -, BCL-2 +, CD23- B-PSL(-) PCBCL N,N,N cut ativ DWD (20)
4 F 63 diss UL, back,palate nodule, plaque 10 10 PCBCL(+)
Anti-CD20 + CD10 +, 
BCL-2 +, CD23+ B-PSL(+) INC N,N,N cut ativ AWD (182)
5 M 50 loc anterior trunk plaque 5 1 INC(-) Anti-CD20 + CD10 +, BCL-2 -, CD23+ B-PSL(+) B-PSL N,N,N cut ativ AWD (135)
6 M 71 reg face, neck, 
trunk, back nodule, plaque 3 20 B-PSL(-)
Anti-CD20 + CD10 -, 
BCL-2 +, CD23+ INC(+) INC N,N,N cut ativ DWD (32)
7 M 67 loc Back plaque 3 1 B-PSL(-) Anti-CD20 + CD10 +, BCL-2 +, CD23-
 
PCBCL(+) PCBCL N,N,N cut ativ AWD (66)
8 F 36 reg UL e LL papule, nodule 2 15 B-PSL Anti-CD20 + CD10 -, BCL-2 +, CD23- B-PSL B-PSL N,N,N cut ativ AWD (43)
9 F 37 diss anterior trunk,back, LL
papule, nodule,
plaque 2 20 PCBCL
Anti-CD20 + CD10 -, 
BCL-2 -, CD23- PCBCL PCBCL N,N,N cut ativ AWD (172)
10 F 62 loc back nodule 1 2 PCBCL(+) Anti-CD20 + CD10 -, BCL-2 +, CD23+ B-PSL(+) INC N,N,N cut rem AND (199)
11 F 43 loc face papule, nodule 0,5 5 B-PSL(-) Anti-CD20 + CD10 +, BCL-2 -, CD23+ PCBCL(+) PCBCL N,N,N cut rem AND (138)
12 F 26 loc back nodule 8 1 INC Anti-CD20 + CD10 -, BCL-2 +, CD23+ INC INC N,N,N cut rem AND (33)
13 M 74 loc anterior 
trunk papule, plaque 5 7 PCBCL
Anti-CD20 + CD10 +, 
BCL-2 -, CD23+ PCBCL PCBCL N,N,N cut ativ AWD (42)
14 M 29 loc back papule, nodule 2 8 PCBCL Anti-CD20 + CD10 -, BCL-2 -, CD23- PCBCL PCBCL N,N,N cut rem AND (179)
15 M 40 loc back plaque 15 1 PCBCL Anti-CD20 + CD10 -, BCL-2 +, CD23- PCBCL PCBCL N,N,N cut rem AND (101)
16 F 40 loc UL papule 1 3 INC(-) Anti-CD20 + CD10 -, BCL-2 +, CD23+ B-PSL(+) B-PSL N,N,N cut rem AND (47)
17 F 62 loc gluteal 
region nodule 3 1 INC
Anti-CD20 + CD10 -, 
BCL-2 +, CD23+ INC INC N,N,N cut ativ AWD (102)
18 F 32 loc UL nodule 1 1 B-PSL Anti-CD20 + CD10 -, BCL-2 +, CD23+ B-PSL B-PSL N,N,N cut rem AND (102)
19 M 65 loc scalp plaque 5 1 PCBCL Anti-CD20 + CD10 +, BCL-2 -, CD23+ PCBCL PCBCL N,N,N cut ativ AWD (36)
20 M 85 loc face papule, nodule 5 3 B-PSL Anti-CD20 + CD10 -, BCL-2 -, CD23- B-PSL B-PSL N,N,N cut ativ AWD (66)
21 M 51 loc face papule, nodule 3 3 B-PSL(-) Anti-CD20 + CD10 +, BCL-2 +, CD23+ INC(+) INC N,N,N cut ativ AWD (96)
22 F 68 loc scalp nodule 3 2 PCBCL Anti-CD20 + CD10 -, BCL-2 -, CD23- PCBCL PCBCL N,N,N cut ativ AWD (62)
23 M 64 loc back nodule 5 1 PCBCL(+) Anti-CD20 + CD10 -, BCL-2 +, CD23+ B-PSL(+) INC N,N,N cut rem AND (60)
24 M 23 loc UL plaque 1 1 PCBCL(+) Anti-CD20 + CD10 +, BCL-2 +, CD23+ B-PSL(+) INC N,N,N cut ativ AWD (96)
25 M 45 diss trunk, UL, LL papule, nodule 2 9 PCBCL(+)
Anti-CD20 + CD10 -, 
BCL-2 +, CD23- INC( -) PCBCL N,N,N cut ativ AWD (40)
26 M 36 diss trunk,
 UL, LL
macula, papule, 
plaque 3 6 INC
Anti-CD20 + CD10 +, 
BCL-2 +, CD23+ INC INC N,N,N cut ativ AWD (92)
27 M 45 loc scalp nodule 1 1 PCBCL Anti-CD20 + CD10 -, BCL-2 +, CD23- PCBCL PCBCL N,N,N cut ativ AWD (50)
28 M 30 loc scalp nodule 2 1 PCBCL Anti-CD20 + CD10 -, BCL-2 +, CD23- PCBCL PCBCL N,N,N cut rem AND (60)
29 M 31 loc scalp nodule 2 1 B-PSL Anti-CD20 + CD10 -, BCL-2 +, CD23+ B-PSL B-PSL N,N,N cut rem AND (55)
I: identification number of the case; G: gender; A: age in years; Dist: distribution of the cutaneous lesions; reg: regional; loc: located; diss: dissemi-
nated; UL: upper limbs; LL: lower limbs; Diam: diameter of the lesions in cm; N: number of lesions; HE: hematoxylin-eosin; IHC: immunohistochem-
istry results; (+): positive or important role in the diagnostic decision; (-) negative or less important role in the diagnostic decision; HE+IHC: diagnosis 
based on HE and IHC; L: lymph node involvement; M: bone marrow involvement; V: visceral involvement; Y: yes; N: no; system: systemic; cut ativ: 
cutaneous in activity; cut rem: cutaneous in remission; Status (period of follow up in months); DWD: dead with active disease; AWD: alive with active 
disease; AND: alive with (no) active disease.
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primers. The reactions were repeated separately or in 
duplicate (two identical reactions using two independent 
samples of DNA from the same case) for result confirmation 
in each case (Figure 2).
RESULTS
Overall, monoclonality was observed in 10 cases, 
polyclonality in 12, and 7 cases were considered non-
informative (Tables 3 and 4). The DNA of all samples 
showed low to moderate quality. When a housekeeping gene 
was analyzed, 8 cases yielded bands of only 100 bp, 15 cases 
yielded bands of 100 and 200 bp, and 6 cases yielded bands 
of 100, 200 and 300 bp. Bands of 400 bp were not observed 
(Figure 1B, Table 3). TCR-gamma rearrangement analysis 
did not reveal evidence of T cell monoclonality in any of the 
29 cases studied.
Analyses of the IgH gene rearrangements in all cases 
were non-informative using the Biomed IgH FR2 method, 
Figure 1A - Clonality analysis of a polyacrylamide gel following electro-
phoresis of PCR products using the IgL -K protocol. (12) Polyclonality 
(broad band, similar to a smear), (13) Monoclonality (well-defined, dominant 
band) and (14) Not defined (absence of bands or bands without definition)
Figure 1B - DNA control: amplification of housekeeping gene fragments of 
100, 200, 300 and 400 bp; lane 1: case 1 presenting a band of 100 bp; lanes 
2, 3 and 4: cases 2, 3 and 4, respectively, each presenting bands of 100 and 
200 bp; lane 5: case 5 showing 3 bands of 100, 200 and 300 bp





Primers- sequences  (5’-3’)
IgH FR2 
Biomed Tube B
250 – 295 bp
VH1-FR2   CTGGGTGCGACAGGCCCCTGGACAA
VH2-FR2   TGGATCCGTCAGCCCCCAGGGAAGG
VH3-FR2   GGTCCGCCAGGCTCCAGGGAA
VH4-FR2   TGGATCCGCCAGCCCCCAGGGAAGG
VH5-FR2   GGGTGCGCCAGATGCCCGGGAAAGG
VH6-FR2   TGGATCAGGCAGTCCCCATCGAGAG
VH7-FR2   TTGGGTGCGACAGGCCCCTGGACAA
JH              CTTACCTGAGGAGACGGTGACC
IgH FR3 
Biomed
100 – 170 bp
VH1-FR3   TGGAGCTGAGCAGCCTGAGATCTGA
VH2-FR3   CAATGACCAACATGGACCCTGTGGA
VH3-FR3   TCTGCAAATGAACAGCCTGAGAGCC
VH4-FR3   GAGCTCTGTGACCGCCGCGGACACG
VH5-FR3   CAGCACCGCCTACCTGCAGTGGAGC
VH6-FR3   GTTCTCCCTGCAGCTGAACTCTGTG
VH7-FR3    CAGCACGGCATATCTGCAGATCAG
JH              CTTACCTGAGGAGACGGTGACC
IgH FR3-trad
80 – 120 bp
FR3           CCGAGGACACGGCCGTGTATTACTG
JH             AACTGCTGAGGAGACGGTGACC
Ig kappa 
130 – 150 bp
TUBE A 
VK1f/6   TCAAGGTTCAGCGGCAGTGGATCTG
VK2f      GGCCTCCATCTCCTGCAGGTCTAGTC
VK3f      CCCAGGCTCCTCATCTATGATGCATCC
VK4        CAACTGCAAGTCCAGCCAGAGTGTTTT
VK5        CCTGCAAAGCCAGCCAAGACATTGAT
VK7        GACCGATTTCACCCTCACAATTAATCC
JK1-4      CTTACGTTTGATCTCCACCTTGGTCCC
JK5         CTTACGTTTAATCTCCAGTCGTGTCCC
TUBE B
VK1f/6   TCAAGGTTCAGCGGCAGTGGATCTG
VK2f       GGCCTCCATCTCCTGCAGGTCTAGTC
VK3f       CCCAGGCTCCTCATCTATGATGCATCC
VK4         CAACTGCAAGTCCAGCCAGAGTGTTTT
VK5         CCTGCAAAGCCAGCCAAGACATTGAT
VK7         GACCGATTTCACCCTCACAATTAATCC
KDE        CCTCAGAGGTCAGAGCAGGTTGTCCTA
INTR       CGTGGCACCGCGAGCTGTAGAC
TCR-gamma 
tubes A and B
145-255 bp (A) 
and 80-220 bp 
(B)
Vγ1f (A)       GGAAGGCCCCACGCRTCTT
Vγ10 (A)      AGCATGGGTAAGACAAGCAA
Vγ9 (B)        CGGCACTGTCAGAAAGGAATC
Vγ11 (B)      CTTCCACTTCCACTTTGAAA
JG11/21       TTACCAGGCGAAGTTACTATGAGC
JG13/23       GTGTTGTTCCACTGCCAAAGAG
Housekeeping 
genes - Biomed
100, 200, 300 
and 400bp
TBXASI-US   GCCCGACATTCTGCAAGTCC  
TBXASI-DS   GGTGTTGCCGGGAAGGGTT  
RAGI-US        TGAGCTGCAAGTTTGGCTGAA 
RAGI-DS        TGTTGACTCGATCCACCCCA  
PLFZ-US        TGCGATGTGGTCATCATGGTG  
PLFZ-DS        CGTGTCATTGTCGTCTGAGGC  
AF4-US          CCGCAGCAAGCAACGAACC  
AF4-DS          GCTTTCCTCTGGCGGCTCC  
From: van Dongen JJ et al. Leukemia 2003 Dec;17(12):2257-317 and 
Diss TC et al. Mol Pathol. 2002 Apr;55(2):98-101.
Figure 2 - Clonality analysis of a polyacrylamide gel following electro-
phoresis of PCR products using the IgH Nizet protocol. Lane 1: positive 
control; lanes 2, 3, 4 and 5: polyclonal results (cases 2 and 4 in duplicate); 
lanes 6 and 7: monoclonal results (case 13 in duplicate); and lanes 8 and 
9: undefined results (case 17 in duplicate)
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and only three cases could be evaluated by the Biomed FR3 
protocol (monoclonality in one case that was considered 
inconclusive at HE and IHC, and polyclonality in two 
cases considered PCBCL and 1 B-PSL, respectively, at HE 
and IHC). The IgH FR3-trad was the most useful protocol 
as 21 cases were conclusively classified. Monoclonality 
was observed in five cases (3 PCBCL and 2 considered 
inconclusive at HE and IHC), and polyclonality was 
observed in 16 cases (6 PCBCL, 4 B-PSL and 6 considered 
inconclusive at HE and IHC) (Tables 3 and 4).
Table 3 - Clonality analysis of the 29 cases with B-cell lymphoproliferative processes
I HE+IHC Clonality HE+IHC+Clon. WHO-EORTC DNA IgH F3 Nizet IgH F3 Biomed IgH F2 IgL kappa TCR
1 PCBCL monoclonal PCBCL follicle center + ND NI NI monoclonal NI
2 INC monoclonal PCBCL follicle center ++ monoclonal NI NI polyclonal polyclonal
3 PCBCL NI PCBCL diffuse large B-cell, leg type ++ NI NI NI NI NI
4 INC polyclonal B-PSL NA ++ polyclonal NI NI polyclonal polyclonal
5 B-PSL NI B-PSL NA +++ NI NI NI NI NI
6 INC polyclonal B-PSL NA ++ polyclonal NI NI polyclonal polyclonal
7 PCBCL monoclonal PCBCL follicle center ++ monoclonal NI NI monoclonal polyclonal
8 B-PSL NI B-PSL NA + NI NI NI NI NI
9 PCBCL monoclonal PCBCL marginal zone ++ monoclonal NI NI monoclonal polyclonal
10 INC NI INC NA + NI NI NI NI NI
11 PCBCL monoclonal PCBCL follicle center +++ polyclonal polyclonal NI monoclonal polyclonal
12 INC polyclonal B-PSL NA + polyclonal NI NI polyclonal NI
13 PCBCL monoclonal PCBCL follicle center ++ monoclonal NI NI monoclonal polyclonal
14 PCBCL NI PCBCL follicle center + NI NI NI NI NI
15 PCBCL NI PCBCL follicle center ++ NI NI NI NI NI
16 B-PSL polyclonal B-PSL NA +++ polyclonal NI NI polyclonal NI
17 INC polyclonal B-PSL NA ++ polyclonal NI NI NI polyclonal
18 B-PSL polyclonal B-PSL NA + polyclonal NI NI NI polyclonal
19 PCBCL monoclonal PCBCL follicle center ++ polyclonal NI NI monoclonal polyclonal
20 B-PSL polyclonal B-PSL NA ++ polyclonal polyclonal NI polyclonal polyclonal
21 INC polyclonal B-PSL NA +++ polyclonal NI NI polyclonal polyclonal
22 PCBCL polyclonal PCBCL follicle center ++ polyclonal NI NI polyclonal polyclonal
23 INC monoclonal PCBCL follicle center +++ monoclonal monoclonal NI monoclonal polyclonal
24 INC polyclonal B-PSL NA + polyclonal NI NI polyclonal polyclonal
25 PCBCL polyclonal PCBCL marginal zone ++ polyclonal NI NI polyclonal polyclonal
26 INC NI INC NA ++ NI NI NI NI NI
27 PCBCL monoclonal PCBCL follicle center + polyclonal NI NI monoclonal polyclonal
28 PCBCL monoclonal PCBCL follicle center ++ polyclonal NI NI monoclonal polyclonal
29 B-PSL polyclonal B-PSL NA +++ polyclonal NI NI polyclonal polyclonal
I: identification number of the case; HE: hematoxylin-eosin; IHC: immunohistochemistry; Clon: Clonality; PCBCL: primary cutaneous B-cell lympho-
ma; INC: inconclusive; NI: non-informative; NA: not applicable; B-PSL: B-cell pseudolymphoma; DNA: quality control of the DNA in each sample; (-) 
absence of DNA in the sample; (+) presence of DNA with 100 bp; (++) presence of DNA with 100 and 200 bp; (+++) presence of DNA with 100, 200 
and 300 bp; TCR: T-cell receptor; NR: number of reactions.
Table 4 - Summary of clonality analysis results of the 29 cases with B-cell lymphoproliferative processes 
HE+IHC Samples Monoclonal Polyclonal Non-informative
PCBCL 13 8 2 3
B-PSL 6 0 4 2
INC 10 2 6 2
HE: hematoxylin-eosin; IHC: immunohistochemistry; PCBCL: primary cutaneous B-cell lymphoma; NI: non-informative; B-PSL: B-cell pseudolym-
phoma; INC: inconclusive.
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Analysis of clonality through investigation of IgL-K gene 
rearrangements yielded results in 20 cases. Monoclonality 
was detected in 9 cases (8 PCBCL and 1 considered 
inconclusive at HE and IHC) and polyclonality in 11 cases 
(2 PCBCL, 3 B-PSL and 6 considered inconclusive at HE 
and IHC) (Tables 3 and 4).
Among the 10 cases considered inconclusive by 
morphology and IHC, monoclonality was demonstrated in 
two cases (20%) by investigation of IgH and IgL kappa gene 
rearrangements (Tables 3 and 4). Despite the small number 
of PCBCL cases, it was possible to observe monoclonality 
in 7 out of 10 cases that had been classified as primary 
cutaneous follicle center lymphoma and in 1 out of 2 cases 
that had been classified as primary cutaneous marginal 
zone B-cell lymphoma, according to the WHO-EORTC 
classification. It was not possible to define clonality in the 
single case of cutaneous diffuse large B-cell lymphoma, 
leg-type, by any of the protocols used in the present report. 
The differential diagnosis between PCBCL and B-PSL 
is relevant for an appropriate follow up and treatment of 
patients with B-cell lymphoproliferative processes. However, 
the differentiation between such entities is complex and 
challenging.24 Since, to date, there is no “gold-standard” 
method that could be autonomously performed for such 
differentiation, this present study evaluated the diagnostic 
contribution of clonality analysis by investigating IgH and 
IgL clonality as an ancillary method to diagnose PCBCL.
The importance of the histological and immuno-
histochemical evaluation in the determination of PCBCL is 
incontestable, even though many cases may remain without 
diagnosis regardless the use of several immunohistochemical 
markers.25,26 In our study, 10 cases were considered 
inconclusive by histology and immunohistochemistry, which 
demonstrates the necessity of additional ancillary diagnostic 
methods. New markers such as IRTA-1 and MUM 1, tissue 
microarrays, chromosomal translocation analysis and 
fluorescence in situ hybridization (FISH) have been used to 
increase the diagnostic accuracy of PCBCL.27-33 
The analysis of clonality by PCR-based tests has played 
an important diagnostic role in PCBCL, but appropriate 
protocols must be selected and optimized to ensure the 
improved diagnostic sensitivity of these techniques. DNA 
quality in the samples is of crucial importance and skin 
biopsies are notoriously poor in this respect. The process of 
tissue fixation in formalin and paraffin embedding variably 
damages the DNA by fragmentation or other mechanisms, 
thus impairing the sensitivity of the test and making it 
difficult to amplify relatively large fragments.14,20,34 These 
observations could explain the low to moderate quality of 
DNA found in our samples and the difficulty in amplifying 
the DNA, especially using the IgH FR2 protocol. This 
protocol amplifies a product of 250-295 bp, requiring a non-
fragmented DNA sample. The same observation was also 
highlighted by other groups.14,19,35
In the present study, we noticed higher sensitivity of 
the IgH FR3 Nizet protocol compared to others (IgH FR3 
Biomed and Ig FR2 Biomed) when the rearrangement of 
IgH genes was investigated. This protocol corroborated the 
diagnosis of three of the PCBCL and four of the B-PSL 
cases. The present finding can also be explained by the 
smaller size of the target DNA. The size of the target product 
in the IgH FR3 Nizet is of 80-120 bp, compatible with the 
DNA size present in the samples, while IgH FR3 Biomed 
and FR2 Biomed amplify larger nucleotide fragments (100-
170 bp and 250-295 bp), requiring well-preserved DNA. 
The main clinical contribution of our molecular 
investigation was the classification of two out of ten 
cases that had been previously considered inconclusive 
by histological and immunohistochemical methods. After 
determination of monoclonality by IgH gene rearrangement, 
these cases could be diagnosed as PCBCL. Although “false-
positive” clonality results in benign cutaneous lesions 
are described in the literature, those two cases presented 
infiltrated lesions on the back that were clinically very 
suggestive of PCBCL (cases 2 and 23). Thus, the clonality 
analysis is of extreme relevance, mainly when analyzed in 
the context of the, histological and immunohistochemical 
data 36
Of subsidiary relevance, but still important, investigation 
of the Ig kappa gene rearrangements supported the previous 
diagnosis of eight of the PCBCL and three of the B-PSL 
cases. Amongst all cases shown to be monoclonal in the 
present study, this result was obtained only by Ig kappa 
gene rearrangement in five cases. It was striking that those 
five cases had a polyclonal result using IgH protocols. This 
finding indicates the need for analysis of both Ig heavy and 
Ig kappa genes.11,19
The importance of a monoclonal result in the 
confirmation of malignancy when analyzing a lymphocytic 
infiltrate is well defined in the literature.10 It is also well 
established that a polyclonal result does not exclude 
a diagnosis of lymphoma due to a high false-negative 
rate.9 In cases in which a diagnosis of PCBCL was made 
by histological and immunohistochemical methods, 
a polyclonal PCR result could be explained by DNA 
amplification of benign reactive cells obscuring the products 
from the expanded clone in addition to the difficulty of 
identification of a well-defined band in the electrophoresis 
gel or by failure of primer annealing to the tumor’s 
rearranged Ig gene segment.9,12,19 Laser-microdissection 
could be used to select specific cells for the DNA extraction 
process, which may improve the sensitivity.37
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Based upon these findings, in our experience, the 
two most efficient molecular methods in this study, IgH 
FR3-trad and Ig kappa Biomed protocols, for analysis of 
formalin–fixed, paraffin-embedded samples could facilitate 
a differential diagnosis between PCBCL and B-PSL. 
Finally, interpretation of the clonality analysis in a clinical, 
histological and immunohistochemical context can be 
critical to the diagnosis of PCBCL.  
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